Sartorius AG (XTER:SRT) 3-Year FCF Growth Rate : 29.40% (As of Mar. 2024)

View and export this data going back to 1990. Start your Free Trial

What is Sartorius AG 3-Year FCF Growth Rate?

Sartorius AG's Free Cash Flow per Share for the three months ended in Mar. 2024 was €-1.20.

During the past 12 months, Sartorius AG's average Free Cash Flow per Share Growth Rate was -19.30% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 29.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 98.80% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 46.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Sartorius AG was 334.50% per year. The lowest was -40.00% per year. And the median was 14.70% per year.

Competitive Comparison of Sartorius AG's 3-Year FCF Growth Rate

For the Medical Instruments & Supplies subindustry, Sartorius AG's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sartorius AG's 3-Year FCF Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Sartorius AG's 3-Year FCF Growth Rate falls into.

Sartorius AG 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Sartorius AG (XTER:SRT) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Sartorius AG 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Sartorius AG's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius AG (XTER:SRT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (XTER:SRT) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

SOAGY:USA SSSGY:USA SUVPF:USA SARTF:USA 1SRT3:Italy SRT3d:UK 0NIR:UK SRT3:Germany SRT3:Austria

Address

Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079

Website

https://www.sartorius.com

Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.